je.st
news
Firm's cancer drugs strategy
2015-09-03 15:23:40| Biotech - Topix.net
Abingdon-based biotechnology firm Immunocore is aiming to make its radical cancer treatment drugs commercially available to patients in the next four years, said the new chief executive officer, Eliot Forster. Dr Forster, who joined the company in January, said: "I would anticipate that, within the next three or four years, we would be selling our lead molecule to patients."
Tags: strategy
cancer
drugs
firms
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||